Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H12N2O4S |
Molecular Weight | 244.268 |
Optical Activity | ( - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@@H]1CSCN1C(=O)[C@@H]2CCC(=O)N2
InChI
InChIKey=UUTKICFRNVKFRG-WDSKDSINSA-N
InChI=1S/C9H12N2O4S/c12-7-2-1-5(10-7)8(13)11-4-16-3-6(11)9(14)15/h5-6H,1-4H2,(H,10,12)(H,14,15)/t5-,6-/m0/s1
DescriptionSources: http://www.thepharmaletter.com/article/focus-on-pidotimod-a-new-biological-response-modifierCurator's Comment: Description was created based on several sources, including
http://www.mims.com/india/drug/info/pidotimod?mtype=generic
http://flipper.diff.org/app/pathways/3840
Sources: http://www.thepharmaletter.com/article/focus-on-pidotimod-a-new-biological-response-modifier
Curator's Comment: Description was created based on several sources, including
http://www.mims.com/india/drug/info/pidotimod?mtype=generic
http://flipper.diff.org/app/pathways/3840
Pidotimod is a synthetic dipeptide with immunomodulatory properties. An immunostimulant used in patients with cell-mediated immunodepression during resp and urinary tract infections. In vitro and in vivo laboratory studies show that treatment with pidotimod causes a significant induction of macrophage and neutrophil polymorphonuclear activity, which is characterized by an increase in spontaneous chemotaxis, superoxide anion production and phagocytosis. Several placebo-controlled trials of the drug have been carried out in various indications such as recurrent respiratory, pharyngotonsillar and urinary infections in children, and in adults with exacerbations of chronic bronchitis. For example, in 120 children with recurrent respiratory infections, pidotimod reduced relapse by 35%, hospitalization by 86% and antibiotic use by 47% compared to placebo.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P59046 Gene ID: 91662.0 Gene Symbol: NLRP12 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25620184 |
|||
Target ID: CHEMBL4163 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23663325 |
|||
Target ID: CHEMBL1778 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7857357 |
|||
Target ID: GO:0042267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1294620 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Pidotimod Approved UsePidotimod is an immunostimulant used in patients with cell-mediated immunodepression during respiratory and urinary tract infections. |
|||
Primary | Pidotimod Approved UsePidotimod is an immunostimulant used in patients with cell-mediated immunodepression during respiratory and urinary tract infections. |
Sample Use Guides
Take this medication by mouth, usually 2 to 3 times daily with a full glass of water (8 ounces or 240 milliliters) or as directed by your doctor. Do not lie down for at least 10 minutes after taking this drug.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23663325
Pidotimod 10 and 100 ug/ml increased TLR-2 expression in BEAS-2B cell line (human bronchial epithelial cells infected with a replication-defective Adenovirus 12-SV40 virus hybrid)
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QL03AX05
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
||
|
WHO-ATC |
L03AX05
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
||
|
NCI_THESAURUS |
C2139
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB09826MIG
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL1488165
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | |||
|
40450
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | RxNorm | ||
|
DB11364
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | |||
|
121808-62-6
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | |||
|
759841
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | |||
|
100000081925
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | |||
|
C76686
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | |||
|
65944
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | |||
|
m8801
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
2164
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | |||
|
DTXSID0046199
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | |||
|
785363R681
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | |||
|
PIDOTIMOD
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | |||
|
C064893
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY | |||
|
6491
Created by
admin on Sat Dec 16 17:44:24 GMT 2023 , Edited by admin on Sat Dec 16 17:44:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY